You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recombinant Novel Coronavirus Vaccine

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Trial in Changsha (Recombinant Novel Coronavirus vaccine (CHO Cells))

Completed
  • COVID-19
  • Recombinant Novel Coronavirus vaccine (CHO Cells)
  • Changsha, Hunan, China
    Hunan Provincial Center for Disease Control and Prevention
Jun 6, 2023

COVID-19 Trial in Taizhou (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus

Completed
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
  • Taizhou, Jiangsu, China
    Taixing City center for Disease Control and Prevention
Oct 28, 2022

COVID-19 Trial in Yancheng (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel

Active, not recruiting
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
  • Yancheng, Jiangsu, China
    Funing Center for Disease Control and Prevention
Oct 28, 2022

COVID-19 Vaccine Trial in Ciudad autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autónoma de Buenos Aires

Active, not recruiting
  • COVID-19 Vaccine
  • Ad5-nCov
  • Ciudad autónoma de Buenos Aires, Buenos Aires, Argentina
  • +2 more
Sep 28, 2022

Coronavirus Trial (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel

Not yet recruiting
  • Coronavirus
  • Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
  • Recombinant novel coronavirus protein vaccine (CHO cells)
  • (no location specified)
Sep 5, 2023

Coronavirus Trial in Wuhu (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant

Active, not recruiting
  • Coronavirus
  • Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
  • Recombinant novel coronavirus protein vaccine (CHO cells)
  • Wuhu, Anhui, China
    Wannan Medical College Yijishan Hospital
May 6, 2023

COVID-19 Trial in Hangzhou (Recombinant novel coronavirus vaccine (CHO cells))

Recruiting
  • COVID-19
  • Recombinant novel coronavirus vaccine (CHO cells)
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial Center for Disease Control and Prevention
Jan 11, 2022

COVID-19 Trial in Hangzhou (Recombinant novel coronavirus vaccine (CHO cells))

Active, not recruiting
  • COVID-19
  • Recombinant novel coronavirus vaccine (CHO cells)
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial Center for Disease Control and Prevention
Jan 11, 2022

Prevention of COVID-19 Trial in Changsha (Recombinant novel coronavirus vaccine (CHO cells))

Active, not recruiting
  • Prevention of COVID-19
  • Recombinant novel coronavirus vaccine (CHO cells)
  • Changsha, Hunan, China
    Hunan Provincial Center for Disease Control and Prevention
Feb 6, 2022

Prevention of COVID-19 Trial in Changsha (Recombinant novel coronavirus vaccine (CHO cells))

Active, not recruiting
  • Prevention of COVID-19
  • Recombinant novel coronavirus vaccine (CHO cells)
  • Changsha, Hunan, China
    Hunan Provincial Center for Disease Control and Prevention Preve
Feb 6, 2022

COVID-19 Trial (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Placebo)

Not yet recruiting
  • COVID-19
  • Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
  • Placebo
  • (no location specified)
Sep 22, 2023

COVID-19 Trial in Tashkent (Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells), Recombinant Novel

Recruiting
  • COVID-19
  • Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
  • Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
  • Tashkent, Uzbekistan
    Uzbekistan, Tashkent city, Said baraka street 10
Nov 11, 2022

Coronavirus Disease 2019 Trial in Changsha (Recombinant new coronavirus vaccine (CHO cell) group)

Completed
  • Coronavirus Disease 2019
  • Recombinant new coronavirus vaccine (CHO cell) group
  • Changsha, Hunan, China
    Hunan Provincial Center for Disease Control and Prevention
Oct 21, 2021

Covid19 Trial in Caba, Capital Federal (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV))

Recruiting
  • Covid19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
  • Caba, Buenos Aires, Argentina
  • +3 more
Sep 14, 2021

COVID-19 Trial in Nanjing (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel

Recruiting
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
  • +3 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincal Center for Disease Control and Prevention
Jul 27, 2021

Coronavirus Disease 2019 Trial in Changsha (Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO

Recruiting
  • Coronavirus Disease 2019
  • Tetravalent influenza virus lysis vaccine
  • Recombinant new coronavirus vaccine (CHO cell) group
  • Changsha, Hunan, China
    Hunan Provincial Center for Disease Control and Prevention
Nov 3, 2021

COVID-19 Trial in Wuhan (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector))

Completed
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Wuhan, Hubei, China
    Hubei Provincial Center for Disease Control and Prevention
Aug 2, 2021

COVID-19 Trial (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type

Not yet recruiting
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
  • (no location specified)
Jan 11, 2022

Covid19 Trial in Russian Federation (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo)

Active, not recruiting
  • Covid19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Placebo
  • Ekaterinburg, Russian Federation
  • +6 more
Jul 19, 2021

Coronavirus Trial in Chongqing (Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus

Unknown status
  • Coronavirus
  • Recombinant new coronavirus vaccine (CHO cell) low-dose group
  • +2 more
  • Chongqing, Chongqing, China
    The Second Affiliated Hospital of Chongqing Medical University
Dec 1, 2020

Coronavirus Trial in Hunan (Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus vaccine

Active, not recruiting
  • Coronavirus
  • Recombinant new coronavirus vaccine (CHO cell) low-dose group
  • +2 more
  • Hunan, Changsha, China
    Hunan Provincial Center for Disease Control and Prevention
Dec 1, 2020

Prevention of COVID-19, Safety and Efficacy Trial in Worldwide (Recombinant new coronavirus vaccine (CHO cell) group,

Active, not recruiting
  • Prevention of COVID-19
  • Safety and Efficacy
  • Recombinant new coronavirus vaccine (CHO cell) group
  • Recombinant new coronavirus vaccine (CHO cells) placebo group
  • Changsha, Hunan, China
  • +17 more
Jan 17, 2022

COVID-19 Trial in Changsha (Recombinant new coronavirus vaccine (CHO cell))

Recruiting
  • COVID-19
  • Recombinant new coronavirus vaccine (CHO cell)
  • Changsha, Hunan, China
    Hunan Provincial Center for Disease Control and Prevention
Jun 2, 2023

COVID-19 Trial in Changsha (Recombinant new coronavirus vaccine (CHO cell))

Recruiting
  • COVID-19
  • Recombinant new coronavirus vaccine (CHO cell)
  • Changsha, Hunan, China
    Hunan Provincial Center for Disease Control and Prevention
Oct 10, 2022

COVID-19 Trial in Nanjing (Recombinant COVID-19 vaccine (Sf9 cells), Placebo)

Withdrawn
  • COVID-19
  • Recombinant COVID-19 vaccine (Sf9 cells)
  • Placebo
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
May 21, 2021